Epiminder team members standing together on building steps

Innovating epilepsy care

At Epiminder, we strive to transform epilepsy management through cutting-edge technology and patient-focused solutions.

Discover the journey of innovation at Epiminder since 2017

Epiminder was founded in 2017 by Professor Mark Cook as a research collaboration between the Bionics Institute, the University of Melbourne, St Vincent's Hospital Melbourne and Cochlear.

The partnership combined the technological expertise in epilepsy seizure monitoring of the three research institutions with Cochlear's proficiency in implant design, development and manufacturing.

Professor Mark Cook demonstrating an epilepsy monitoring device with a brain model

Professor Mark Cook examining the Minder Implant device, the world's first FDA-authorised* implantable continuous EEG monitoring systemPicture: Aaron Francis, The Australian, May 7, 2021

Key milestones in our journey

Since our founding in 2017, Epiminder has been dedicated to revolutionising epilepsy care. Our innovative technology aims to empower patients and improve their quality of life.

2017

Epiminder founded by Bionics Institute, Cochlear, St Vincent's Hospital and Melbourne University.

2019

Epiminder develops prototype Minder implantable continuous EEG monitoring (iCEM) device, a multi-year duration ssEEG unit.

2019

First of kind UMPIRE clinical study of Minder commences at leading tertiary research hospitals in Victoria, Queensland and New South Wales.

2023

Minder receives FDA "Breakthrough" designation, for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Device Designation (BDD) program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review.

2023

Professor Cook received the Order of Australia in recognition of his distinguished service to neurological medicine and research through contributions to the treatment of epilepsy.

2024

UMPIRE clinical study completes, with results demonstrating that Minder is both safe and has signal detection equivalent to a scalp EEG. Minder achieves a significant milestone, having recorded continuous EEG for five years in a study participant. To date, this is the longest continuous EEG recording ever captured.

2025

Epiminder received FDA marketing authorization via the De Novo pathway allowing its sale and marketing in the US.

Executive leadership

Our leadership team brings together expertise from neurology, biomedical engineering, and healthcare technology.

Dr Rohan Hoare

Dr Rohan Hoare

Chief Executive Officer

View bio
Prof Mark Cook, AO

Prof Mark Cook, AO

Chief Medical Officer

View bio
Dr John Heasman

Dr John Heasman

Chief Operating Officer

View bio
Toby McSweeney

Toby McSweeney

Chief Technology Officer

View bio
Dr Tracy Cameron

Dr Tracy Cameron

VP, Clinical & Regulatory

View bio
Chip Moebus

Chip Moebus

VP, Market Access

View bio
Steven Ringo

Steven Ringo

VP, IT & Security

View bio

Board of Directors

Philip Binns

Philip Binns

Chair

View bio
Dr Rohan Hoare

Dr Rohan Hoare

Chief Executive Officer & Managing Director

View bio
Robert Klupacs

Robert Klupacs

Non-Executive Director

View bio
Donal O'Dwyer

Donal O'Dwyer

Independent Non-Executive Director

View bio
Patricia O'Rourke

Patricia O'Rourke

Non-Executive Director

View bio
Jeff Sells

Jeff Sells

Independent Non-Executive Director

View bio
Karen Campitelli

Karen Campitelli

Company Secretary

View bio

In proud partnership with

Cochlear logoBionics Institute logoSt Vincent's Health Australia logoThe University of Melbourne logo